UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~April 175, 2012

ZYTO CORP

(Exact name of Registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	000-54170 (Commission File Number)	20-5534033 (IRS Employer Identification Number)

	387 South 520 West, Suite 200 Lindon, UT 84042

801-224-7199 (Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 87.01 ~~Other~~ ~~Items.~~Regulation FD Disclosure

OnWebinar ~~January~~Discussing ~~23, 2012, ZYTO Corp (the “~~Company”) ~~announced~~Results ~~that it had received notice~~ and confirmation from the United States Patent and Trademark Office (“USPTO”) stating that the Company’s patent application for “Methods and Devices for Analyzing and Comparing Physiological Parameter Measurements” (the “Patent”) was issued on January 17, 2012, and given Patent No. 8,099,159.Events

~~The~~On ~~Patent~~Thursday, ~~covers~~April ~~the~~5, ~~methods~~2012, ~~and~~ZYTO ~~devices~~Corp, ~~that~~a ~~are~~Delaware ~~capable~~corporation of(the ~~measuring~~“Company” ~~physiological~~or ~~parameters~~“ZYTO”), ofhosted ata ~~least~~web-based ~~two~~seminar, ~~contact~~or ~~points~~webinar ~~and determining whether~~ (the ~~measured~~“Webinar”), ~~parameters~~during ~~reflect~~which ~~favorable~~Dr. orVaughn ~~unfavorable~~R ~~physiological~~Cook, ~~responses~~the ~~are~~founder ~~disclosed~~and ~~herein.~~CEO Asof ~~noted~~ZYTO indiscussed the ~~application~~Company’s ~~for~~2011 ~~the~~results ~~Patent~~as ~~filed~~well ~~with~~as ~~the~~upcoming ~~USPTO,~~events. During the ~~invention~~Webinar, ~~encompasses~~which awas ~~method~~open ~~that~~to ~~can~~the ~~non-invasively~~public, ~~monitor~~Dr. ~~physiological~~Cook ~~parameters~~provided ofthe atCompany’s ~~least~~shareholders ~~two~~and ~~contact~~the ~~points~~general ~~before~~public ~~and~~an ~~after~~overall abusiness ~~stimulus~~update, isincluding ~~applied to~~ a ~~subject~~discussion ~~and~~of ~~compare~~ the ~~measured~~Company’s ~~parameters~~2011 tofinancial ~~determine~~results, ~~whether~~recent ~~the~~developments, ~~physiological~~and ~~state~~the ofCompany’s ~~the~~upcoming ~~subject~~Annual isConference ~~favorable~~on orMay ~~unfavorable~~4-5, 2012.

~~The~~People ~~Company~~who ~~uses~~attended and viewed the ~~patented~~Webinar ~~method~~were ofable ~~measuring~~to see slides highlighting the ~~skin’s~~information ~~galvanic~~discussed ~~response~~by toDr. ~~stimuli~~Cook. A tocopy ~~provide~~of ~~information~~the toslides ~~healthcare~~presented ~~professionals~~at ~~about~~the Webinar is attached as an ~~individual’s~~Exhibit ~~health~~to ~~and~~this ~~healthcare~~Current ~~options~~Report.

DrAn archived presentation of the Webinar may be viewed at the following URL: https://www1.gotomeeting.com/register/873084433. ~~Vaughn~~The RURL ~~Cook~~of the website where the Webinar may be viewed is ~~listed~~included herein as an inactive textual reference. Information contained on, or accessible through, the ~~inventor~~website linked is not a part of, and Dris not incorporated by reference into, this Report. Additionally, ~~Cook~~because ~~has~~the ~~assigned~~site where the ~~Patent~~Webinar tois hosted is not owned or controlled by the Company, there can be no assurance of how long the archived Webinar will remain available.

The ~~grant~~information offurnished ~~the~~under ~~Patent~~this ~~follows~~Item ~~the~~7.01 ~~notification~~and ~~received~~Item ~~from~~9.01 ~~the~~of USthis ~~Food~~Current ~~and~~Report ~~Drug~~on ~~Administration~~Form ~~(the~~8-K, ~~“FDA”)~~including inExhibit ~~August 2011~~99.1, ~~that~~shall ~~the~~not ~~Company’s~~be ~~Premarket~~deemed ~~Notification~~to ~~(the~~be “~~Notification~~filed”), ~~submitted~~for ~~pursuant~~the topurposes of Section ~~510(k)~~18 of the ~~U.S.~~Securities ~~Food~~Exchange Act of 1934, ~~Drug~~as ~~and~~amended, ~~Cosmetic~~or ~~Act~~otherwise (subject to the ~~“Act”)~~liabilities ~~had~~of ~~been~~that ~~approved. The~~section, ~~Company~~nor ~~filed~~shall ~~the~~it ~~Notification~~be indeemed ~~May~~incorporated ofby ~~2011,~~reference ~~and~~in onany ~~August~~registration ~~30,~~statement ~~2011,~~or other filing under the ~~FDA~~Securities ~~issued~~Act ~~its~~of ~~determination~~1933, ~~that~~as ~~the~~amended, ~~Hand~~except ~~Cradle~~as ~~was~~shall ~~substantially~~be ~~equivalent~~expressly toset ~~other~~forth ~~Galvanic~~by ~~skin~~specific ~~response~~reference ~~measurement~~in ~~devices~~any such filing.

Item 79.01~~. Regulation~~ FDFinancial ~~Disclosure~~Statements and Exhibits.

On January 23, 2012, the Company issued a press release announcing the grant of the Patent by the USPTO. The press release is attached hereto as Exhibit 99.1 to this Report.

Exhibit No.	Description

99.1	Copy of Webinar Slides

In accordance with General Instruction B.2 of Form 8-K, the information in this section of this Report shall not be deemed filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing.

Item 9.01 Financial Statements and Exhibits

	(d)	Exhibits.
		99.1	Press Release dated January 23, 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

	ZYTO Corp
Date: January 23, 2012	By: /s/ Vaughn R Cook
Date: April 9, 2012	By:	/s/ Vaughn R Cook
	Name: Vaughn R Cook
	Title: Chief Executive Officer

Filing Compare · ZYTO CORP